News

Praxis has raised another $110M to advance its ion channel drugs

BY      |     July 28, 2020

Praxis Precision Medicines, a clinical-stage genetic neuroscience company, that develops therapies for complex and debilitating brain disorders, announced that it has raised anoter $110 Million to advance its ion channel drugs for the treatment of neurological disorders.

Praxis has now 3 clinical-stage assets: PRAX-114, a GABAA positive allosteric modulator, currently in Phase 2 development for the treatment of major depressive disorder and perimenopausal depression; PRAX-944, a T-type calcium channel blocker, currently in Phase 2 development for the treatment of essential tremor; and PRAX-562, currently in Phase 1 development for the treatment of pediatric epilepsy and adult cephalgia.

Other treatments, PRAX-020/021 and PRAX-222, are in preclinical development for genetic epilepsies.

Read the press release here.

Read more about Praxis here.



Image by Ahmed Gad from Pixabay


Comments? Questions? Suggestions?

If you have any comments, questions or suggestions concerning this article, feel free to email me at [email protected]
Alternatively, you can leave your comments on LinkedIn or Twitter.